Quick Answer
VitaNova Life Sciences Corp reported Total Revenue of $2.66 million for fiscal year 2025.
VitaNova Life Sciences Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $2.66M +366.5% |
$570.7K +1401.8% |
$38.0K -68.3% |
$120.0K | $0.00 | $0.00 |
| Revenue (ASC 606) | $2.66M +366.5% |
$570.7K +1401.8% |
$38.0K | — | — | — |
| Net Income | $850.7K +503.9% |
$140.9K +681.4% |
-$24.2K -117.3% |
$139.7K +368.1% |
-$52.1K +28.0% |
-$72.3K +31.9% |
| Diluted EPS | $0.03 +200.0% |
$0.01 | $0.00 -100.0% |
$0.02 +300.0% |
-$0.01 | — |
| Total Assets | $2.26M +89.1% |
$1.19M +13567.0% |
$8.7K -62.2% |
$23.1K | $0.00 | $0.00 |
| Cash and Equivalents | — | — | $8.7K -62.2% |
$23.1K | $0.00 | $0.00 |
| Stockholders Equity | $1.91M +80.8% |
$1.06M +1883.2% |
-$59.2K -69.2% |
-$35.0K +80.0% |
-$174.7K -42.5% |
-$122.6K -144.0% |
| Operating Income | $1.21M +487.6% |
$205.6K +948.8% |
-$24.2K -81.2% |
-$13.4K +74.3% |
-$52.1K +28.0% |
-$72.3K -0.7% |
| Gross Profit | $1.58M +317.2% |
$377.7K +894.0% |
$38.0K | — | — | — |
| Shares Outstanding | 25.01M +0.0% |
25.01M +326.0% |
5.87M +0.0% |
5.87M +0.0% |
5.87M +0.0% |
5.87M +0.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | January 31, 2026 | $709.6K | +130.2% | +66.1% |
| Revenue (ASC 606) | January 31, 2026 | $709.6K | +130.2% | +66.1% |
| Net Income | January 31, 2026 | -$44.4K | -160.8% | -223.9% |
| Diluted EPS | January 31, 2026 | -$0.01 | -200.0% | — |
| Total Assets | January 31, 2026 | $2.31M | +75.0% | -1.0% |
| Cash and Equivalents | January 31, 2024 | $808.4K | +7240.0% | — |
| Stockholders Equity | January 31, 2026 | $1.85M | +67.3% | -2.3% |
| Operating Income | January 31, 2026 | $46.7K | -57.1% | -52.9% |
| Gross Profit | January 31, 2026 | $316.3K | +67.1% | +21.3% |
| Shares Outstanding | October 31, 2025 | 25.01M | +0.0% | +0.0% |
- VitaNova Life Sciences Corp reported Total Revenue of $2.66 million for fiscal year 2025.
- VitaNova Life Sciences Corp showed an increase of +366.5% in Total Revenue compared to the prior fiscal year.
- VitaNova Life Sciences Corp reported Revenue (ASC 606) of $2.66 million for fiscal year 2025.
- VitaNova Life Sciences Corp showed an increase of +366.5% in Revenue (ASC 606) compared to the prior fiscal year.
- VitaNova Life Sciences Corp reported Net Income of $850.7 thousand for fiscal year 2025.
- VitaNova Life Sciences Corp showed an increase of +503.9% in Net Income compared to the prior fiscal year.
- VitaNova Life Sciences Corp reported Diluted EPS of $0.03 per share for fiscal year 2025.
- VitaNova Life Sciences Corp showed an increase of +200.0% in Diluted EPS compared to the prior fiscal year.
- VitaNova Life Sciences Corp reported Total Assets of $2.26 million for fiscal year 2025.
- VitaNova Life Sciences Corp showed an increase of +89.1% in Total Assets compared to the prior fiscal year.
- VitaNova Life Sciences Corp reported Cash and Equivalents of $8.7 thousand for fiscal year 2023.
- VitaNova Life Sciences Corp showed a decrease of -62.2% in Cash and Equivalents compared to the prior fiscal year.
- VitaNova Life Sciences Corp reported Stockholders Equity of $1.91 million for fiscal year 2025.
- VitaNova Life Sciences Corp showed an increase of +80.8% in Stockholders Equity compared to the prior fiscal year.
- VitaNova Life Sciences Corp reported Operating Income of $1.21 million for fiscal year 2025.
- VitaNova Life Sciences Corp showed an increase of +487.6% in Operating Income compared to the prior fiscal year.
- VitaNova Life Sciences Corp reported Gross Profit of $1.58 million for fiscal year 2025.
- VitaNova Life Sciences Corp showed an increase of +317.2% in Gross Profit compared to the prior fiscal year.
- VitaNova Life Sciences Corp reported Shares Outstanding of 25.01 million shares for fiscal year 2025.
- VitaNova Life Sciences Corp showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: